



# MYANMAR

Number of new cases

**77 603**

Number of deaths

**54 841**

Number of prevalent cases (5-year)

**156 677**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	26 616 518	28 610 634	55 227 152
<b>Incidence*</b>			
Number of new cancer cases	35 822	41 781	77 603
Age-standardized incidence rate	147.2	129.8	135.5
Risk of developing cancer before the age of 75 years (cum. risk %)	15.2	13.1	13.9
Top 3 leading cancers (ranked by cases)**	Lung Liver Stomach	Breast Cervix uteri Lung	Lung Breast Cervix uteri
<b>Mortality*</b>			
Number of cancer deaths	27 518	27 323	54 841
Age-standardized mortality rate	114.9	85.1	97.1
Risk of dying from cancer before the age of 75 years (cum. risk %)	12.1	9.1	10.4
Top 3 leading cancers (ranked by deaths)**	Lung Liver Stomach	Cervix uteri Lung Breast	Lung Liver Stomach
<b>Prevalence*</b>			
5-year prevalent cases	65 709	90 968	156 677



## Top 5 most frequent cancers\*\*

**Males**




Total: 35 822

Rank	Cancer site	Number of cases	Percent
1st	Lung	4 983	13.9%
2nd	Liver	4 003	11.2%
3rd	Stomach	3 753	10.5%
4th	Oesophagus	2 959	8.3%
5th	Colorectum	2 843	7.9%
-	Others	17 281	48.2%

Number of new cases in 2022, males, all ages

**Females**




Total: 41 781

Rank	Cancer site	Number of cases	Percent
1st	Breast	7 644	18.3%
2nd	Cervix uteri	7 028	16.8%
3rd	Lung	3 885	9.3%
4th	Stomach	2 917	7.0%
5th	Colorectum	2 709	6.5%
-	Others	17 598	42.1%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 77 603

Rank	Cancer site	Number of cases	Percent
1st	Lung	8 868	11.4%
2nd	Breast	7 644	9.9%
3rd	Cervix uteri	7 028	9.1%
4th	Stomach	6 670	8.6%
5th	Liver	6 072	7.8%
-	Others	41 321	53.2%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Lung	8 868	1	11.4	1.9	8 145	1	14.9	1.8	12 547	22.7
Breast	7 644	2	9.9	2.4	3 271	7	6.0	1.1	19 133	66.9
Cervix uteri	7 028	3	9.1	2.2	4 374	4	8.0	1.5	17 908	62.6
Stomach	6 670	4	8.6	1.4	5 740	3	10.5	1.2	10 757	19.5
Liver	6 072	5	7.8	1.2	5 889	2	10.7	1.2	8 377	15.2
Colorectum	5 552	6	7.2	1.1	3 282	6	6.0	0.64	12 541	22.7
Oesophagus	4 001	7	5.2	0.81	3 836	5	7.0	0.78	6 426	11.6
Lip, oral cavity	2 495	8	3.2	0.47	1 452	9	2.6	0.28	5 750	10.4
Nasopharynx	2 097	9	2.7	0.37	1 443	10	2.6	0.27	5 222	9.5
NHL	1 959	10	2.5	0.37	1 229	11	2.2	0.24	4 991	9.0
Leukaemia	1 898	11	2.4	0.29	1 564	8	2.9	0.25	4 603	8.3
Ovary	1 813	12	2.3	0.57	1 156	12	2.1	0.39	4 403	15.4
Thyroid	1 716	13	2.2	0.27	254	23	0.46	0.05	4 579	8.3
Hypopharynx	1 368	14	1.8	0.28	918	14	1.7	0.18	2 176	3.9
Larynx	1 286	15	1.7	0.26	804	15	1.5	0.16	3 169	5.7
Brain CNS	1 119	16	1.4	0.20	984	13	1.8	0.18	3 112	5.6
Bladder	1 012	17	1.3	0.21	582	18	1.1	0.12	2 411	4.4
Gallbladder	999	18	1.3	0.20	794	16	1.4	0.16	1 466	2.7
Prostate	904	19	1.2	0.52	392	20	0.72	0.16	1 698	6.4
Corpus uteri	902	20	1.2	0.31	283	22	0.52	0.11	2 538	8.9
Pancreas	754	21	0.97	0.16	741	17	1.4	0.16	878	1.6
Oropharynx	673	22	0.87	0.13	396	19	0.72	0.08	1 519	2.8
Kidney	555	23	0.72	0.11	364	21	0.66	0.07	1 248	2.3
Penis	347	24	0.45	0.16	177	25	0.32	0.07	790	3.0
Salivary glands	261	25	0.34	0.05	93	27	0.17	0.02	661	1.2
Multiple myeloma	246	26	0.32	0.05	211	24	0.39	0.04	529	0.96
Testis	153	27	0.20	0.04	41	30	0.08	0.01	455	1.7
Vulva	151	28	0.20	0.06	55	28	0.10	0.02	372	1.3
Melanoma	147	29	0.19	0.02	99	26	0.18	0.01	364	0.66
Hodgkin lymphoma	114	30	0.15	0.02	49	29	0.09	0.01	305	0.55
Vagina	68	31	0.09	0.04	38	31	0.07	0.02	145	0.51
Kaposi sarcoma	14	32	0.02	0.00	5	33	0.01	0.00	12	0.02
<b>All cancers</b>	<b>77 603</b>	-	-	<b>13.9</b>	<b>54 841</b>	-	-	<b>10.4</b>	<b>156 677</b>	-
<b>All cancers excl. NMSC</b>	<b>76 043</b>	-	-	<b>13.7</b>	<b>54 218</b>	-	-	<b>10.3</b>	<b>152 623</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** No data: the rates are those of neighbouring countries or registries in the same area

### Mortality

**Country-specific data source:** No data  
**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

